MIRA Pharmaceuticals is a pre-revenue oral-neurology company that just completed the only clinical job a Phase One shop can complete, and completed it into a treasury that cannot carry the next study alone. Unblinded healthy-volunteer work on Ketamir-2, an oral modulator of the NMDA receptor that ketamine also hits, showed no serious adverse events and no dropouts across the enrolled cohorts. That package is the permission slip to file a chemotherapy-neuropathy protocol. A permission slip is not a funded trial, and the second-quarter accounts make that distinction uncomfortably clear.
The print is the cost of staying small enough to survive. Research spending rose as Ketamir-2 moved from healthy volunteers toward a patient study, while general and administrative costs fell sharply because last year's stock-based pay wave did not repeat. Cash ended mid-year near $4 million. Management describes that balance as enough to reach early next year and simultaneously says it is not enough for twelve months from issuance, which is how a going concern paragraph is written. The market is not watching a margin story. It is watching whether the next financing arrives before the science needs a check the company cannot write.
Nasdaq added a second clock when a July notice said the bid had stayed under one dollar for thirty sessions, with a late-January cure window and a reverse-split path if that window is missed. Related-party licensor MIRALOGX expanded the three-program territories to worldwide rights in May and June, which tidies partnership optionality without putting cash on the balance sheet. The question the next two quarters resolve is whether the CIPN protocol can be capitalized and opened before the listing cure and the cash runway meet.